Knee pain is a common clinical symptom associated with osteoarthritis, cartilage degeneration, synovitis, meniscal injury, subchondral bone stress, ligament strain, and altered joint biomechanics. Umbilical cord-derived mesenchymal stem cells, or UC-MSC stem cell therapy, have been investigated in regenerative orthopedics because of their paracrine, immunomodulatory, anti-inflammatory, and tissue-supportive properties. In knee osteoarthritis, the rationale for UC-MSC stem cell therapy is not simple cartilage replacement, but modulation of the intra-articular environment, including inflammatory signaling, synovial activity, extracellular matrix metabolism, and repair-related communication. This review summarizes the clinical rationale, proposed mechanisms, patient-selection criteria, procedural considerations, safety issues, outcome monitoring, and current limitations of UC-MSC stem cell therapy for knee pain in Thailand.
Introduction
Knee pain is one of the most frequent causes of reduced mobility in adults. It may affect walking, stair climbing, exercise tolerance, sleep, work, and quality of life. Although patients often describe the problem simply as “knee pain,” the underlying diagnosis may vary significantly.
Knee osteoarthritis is one of the most common causes. It is a whole-joint disease involving cartilage thinning, synovial inflammation, subchondral bone remodeling, meniscal degeneration, osteophyte formation, ligament changes, and neuromuscular dysfunction. Pain may arise not only from cartilage loss, but also from inflamed synovium, bone marrow lesions, joint capsule irritation, meniscal pathology, tendon overload, or abnormal mechanical loading.
UC-MSC stem cell therapy has gained attention as a regenerative orthopedic option. However, it should not be described as a guaranteed non-surgical solution or a proven method for complete joint regeneration. A medical discussion should define it as an investigational and supportive approach that may be considered in selected patients after clinical and imaging review.
Pathophysiology of Knee Osteoarthritis
Knee osteoarthritis is not only a disease of cartilage wear. It is a complex biological and mechanical process. Articular cartilage contains chondrocytes embedded in an extracellular matrix rich in collagen and proteoglycans. With aging, injury, inflammation, metabolic stress, and abnormal load, this matrix may progressively degrade.
Synovial inflammation can contribute to pain, swelling, stiffness, and further cartilage catabolism. Subchondral bone changes may alter joint loading and contribute to pain. Meniscal degeneration can increase contact stress across the joint. Muscle weakness and poor alignment may further accelerate symptoms.
Because multiple structures contribute to knee pain, treatment should be based on diagnosis rather than a single procedure. A patient with mild synovitis and early cartilage thinning differs from a patient with severe varus deformity, bone-on-bone arthritis, or unstable meniscal damage.
Figure 1: How Knee Osteoarthritis Progresses From Healthy Cartilage to Joint Degeneration
What Are UC-MSCs?
UC-MSC stem cell therapy are mesenchymal stem or stromal cells derived from umbilical cord tissue, commonly from Wharton’s jelly. They are collected after healthy birth with donor consent and screening. UC-MSC stem cell therapy are not embryonic stem cells.
In regenerative medicine, UC-MSC stem cell therapy are mainly studied for paracrine signaling. This means they release cytokines, growth factors, extracellular vesicles, chemokines, and other biological mediators that may influence inflammation, immune activity, oxidative stress, microvascular signaling, extracellular matrix metabolism, and tissue repair pathways.
For knee pain, UC-MSC stem cell therapy should not be explained as cells that automatically become new cartilage after injection. A more scientifically appropriate explanation is that UC-MSC stem cell therapy may help support the joint microenvironment through anti-inflammatory and repair-related signaling.
Proposed Mechanisms in Knee Pain and Osteoarthritis
The rationale for UC-MSC stem cell therapy in knee osteoarthritis includes several proposed mechanisms.
First, UC-MSC stem cell therapy may modulate inflammatory signaling inside the joint. Synovitis and inflammatory cytokines can contribute to pain and cartilage degradation.
Second, UC-MSC-derived factors may influence chondrocyte activity and extracellular matrix-related pathways. This may be relevant to cartilage environment support, although it should not be interpreted as guaranteed cartilage regrowth.
Third, UC-MSC stem cell therapy may influence macrophage polarization and immune-cell activity within the joint. A less inflammatory intra-articular environment may support symptom control and tissue homeostasis.
Fourth, extracellular vesicles released by MSC stem cell therapy may carry regulatory molecules involved in cell-to-cell communication and repair signaling.
These mechanisms are biologically plausible but remain under clinical investigation.
Patient Selection
Patient selection is critical. UC-MSC stem cell therapy may be more reasonable to discuss in patients with early to moderate knee osteoarthritis, chronic inflammatory knee pain, cartilage thinning with remaining joint space, or symptoms that persist despite conservative care.
A better candidate may have stable ligament structure, no active infection, no severe deformity, and realistic expectations. Patients should also be willing to participate in rehabilitation, weight management if relevant, and activity modification.
Less suitable candidates may include patients with severe bone-on-bone arthritis, advanced joint collapse, major malalignment, unstable ligaments, active joint infection, recent fracture, tumor-related bone disease, or progressive neurological weakness. In these cases, orthopedic surgical evaluation may be more appropriate.
Imaging and Diagnostic Assessment
Figure 2: Imaging and Diagnostic Assessment Helps Identify the Cause and Severity of Knee Pain
Imaging is important before considering regenerative knee therapy. X-rays can assess joint-space narrowing, osteophytes, alignment, and osteoarthritis grade. MRI can provide more detailed information about cartilage, meniscus, ligaments, bone marrow lesions, synovitis, and subchondral bone.
The treatment plan should correlate imaging findings with symptoms and physical examination. MRI abnormalities do not always equal the pain source. Similarly, pain severity does not always match radiographic grade.
A medical review should clarify whether the main target is synovial inflammation, cartilage degeneration, meniscal pathology, tendon overload, or mechanical instability.
Intra-Articular Injection and Procedural Considerations
For knee osteoarthritis, UC-MSC stem cell therapy is commonly discussed as an intra-articular injection, meaning the cells are delivered into the knee joint. Image guidance using ultrasound or fluoroscopy may improve procedural accuracy, especially in patients with altered anatomy or narrow joint space.
Procedural planning should include sterile technique, dose rationale, route explanation, post-injection monitoring, and activity guidance. Patients may be advised to avoid heavy loading, high-impact activity, and aggressive exercise immediately after treatment.
The injection itself should not be viewed as the complete treatment. Rehabilitation remains important because joint mechanics strongly influence symptoms and long-term function.
Clinical Endpoints and Monitoring
A medical approach should include measurable outcomes. Possible endpoints include:
- Pain score
- WOMAC score
- KOOS score
- Range of motion
- Walking distance
- Stair-climbing tolerance
- Swelling frequency
- Analgesic use
- Physical therapy performance
- MRI or X-ray follow-up when clinically indicated
- Patient-reported quality of life
Symptom improvement should be interpreted carefully. Knee pain can fluctuate with activity, body weight, inflammation, sleep, medications, physiotherapy, and natural disease variation.
Safety and Quality Control
Safety depends on both cell quality and procedural technique. Patients should ask whether the cells are derived from umbilical cord tissue, how donors are screened, whether infectious disease testing is performed, whether sterility and endotoxin testing are completed, whether viability is documented, and whether the final product meets release criteria before use.
Possible risks may include post-injection pain flare, swelling, infection, bleeding, allergic reaction, failure to respond, or worsening symptoms. Although serious complications are uncommon when proper protocols are followed, they should still be discussed during informed consent.
Limitations of Current Evidence
UC-MSC stem cell therapy for knee pain and osteoarthritis remains an evolving area. Clinical studies and reviews suggest potential improvement in pain and function in selected patients, but evidence quality varies. Differences in cell source, dose, preparation method, injection frequency, osteoarthritis grade, follow-up time, and outcome measures make conclusions difficult.
Current evidence is not strong enough to claim that UC-MSC stem cell therapy can cure osteoarthritis, rebuild a severely damaged joint, or replace knee replacement surgery in advanced cases.
Conclusion
UC-MSC stem cell therapy for knee pain is a developing area of regenerative orthopedics based on immune modulation, synovial inflammation control, paracrine signaling, and cartilage-environment support. Its potential role is most appropriately discussed in selected patients with knee osteoarthritis or chronic joint pain where enough joint structure remains for biological support.
However, UC-MSC stem cell therapy should not be presented as a guaranteed non-surgical solution or proven joint regeneration treatment. Clinical use requires diagnosis, imaging review, patient selection, cell-quality control, image-guided technique, rehabilitation planning, and realistic expectations.
The central clinical question is not whether stem cells can “regenerate the knee.” A more appropriate question is whether the patient’s knee pathology has a reasonable biological target for UC-MSC-based support.
When presented with scientific caution and proper monitoring, UC-MSC therapy can be discussed in a medically responsible way for patients seeking knee pain treatment in Thailand.